Dejan Micic to Cholangitis, Sclerosing
This is a "connection" page, showing publications Dejan Micic has written about Cholangitis, Sclerosing.
Connection Strength
0.296
-
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018 Mar; 47(6):753-762.
Score: 0.154
-
Risk of colorectal cancer in chronic liver diseases: a systematic review and meta-analysis. Gastrointest Endosc. 2017 Jul; 86(1):93-104.e5.
Score: 0.142